BRAF and melanoma: KEYNOTE‐006 reported that, among previously BRAF‐mutant advanced melanoma patients, median OS was 20.4 months (95%CI 12.8‐35.6) among those who received pembrolizumab and 11.9 months (95%CI 6.0‐17.8) for those who received ipilimumab (HR = 0.71 [95%CI 0.46‐1.08], P = .054).5